313 related articles for article (PubMed ID: 22981547)
21. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
[TBL] [Abstract][Full Text] [Related]
23. A cost-effectiveness analysis of a hypothetical catheter-based strategy for the detection and treatment of vulnerable coronary plaques with drug-eluting stents.
Bosch JL; Beinfeld MT; Muller JE; Brady T; Gazelle GS
J Interv Cardiol; 2005 Oct; 18(5):339-49. PubMed ID: 16202108
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction.
Rinfret S; Cohen DJ; Lamas GA; Fleischmann KE; Weinstein MC; Orav J; Schron E; Lee KL; Goldman L
Circulation; 2005 Jan; 111(2):165-72. PubMed ID: 15630030
[TBL] [Abstract][Full Text] [Related]
25. Long-term cost-effectiveness of disease management in systolic heart failure.
Miller G; Randolph S; Forkner E; Smith B; Galbreath AD
Med Decis Making; 2009; 29(3):325-33. PubMed ID: 19147835
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.
Gaziano TA; Steyn K; Cohen DJ; Weinstein MC; Opie LH
Circulation; 2005 Dec; 112(23):3569-76. PubMed ID: 16330698
[TBL] [Abstract][Full Text] [Related]
27. Improvement of albuminuria after renal denervation.
Ott C; Mahfoud F; Schmid A; Ditting T; Veelken R; Ewen S; Ukena C; Uder M; Böhm M; Schmieder RE
Int J Cardiol; 2014 May; 173(2):311-5. PubMed ID: 24681017
[TBL] [Abstract][Full Text] [Related]
28. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
29. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension.
Ukena C; Mahfoud F; Kindermann I; Barth C; Lenski M; Kindermann M; Brandt MC; Hoppe UC; Krum H; Esler M; Sobotka PA; Böhm M
J Am Coll Cardiol; 2011 Sep; 58(11):1176-82. PubMed ID: 21884958
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
31. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
; Esler MD; Krum H; Sobotka PA; Schlaich MP; Schmieder RE; Böhm M
Lancet; 2010 Dec; 376(9756):1903-9. PubMed ID: 21093036
[TBL] [Abstract][Full Text] [Related]
32. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.
Littlewood KJ; Greiner W; Baum D; Zoellner Y
BMC Nephrol; 2007 Jul; 8():9. PubMed ID: 17645811
[TBL] [Abstract][Full Text] [Related]
33. Orthostatic function after renal sympathetic denervation in patients with resistant hypertension.
Lenski M; Mahfoud F; Razouk A; Ukena C; Lenski D; Barth C; Linz D; Laufs U; Kindermann I; Böhm M
Int J Cardiol; 2013 Nov; 169(6):418-24. PubMed ID: 24157238
[TBL] [Abstract][Full Text] [Related]
34. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
Acta Ophthalmol; 2014 Sep; 92(6):513-23. PubMed ID: 24330516
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors.
Hayashino Y; Nagata-Kobayashi S; Morimoto T; Maeda K; Shimbo T; Fukui T
J Gen Intern Med; 2004 Dec; 19(12):1181-91. PubMed ID: 15610328
[TBL] [Abstract][Full Text] [Related]
36. Renal denervation.
Olsen LK; Kamper AL; Svendsen JH; Feldt-Rasmussen B
Eur J Intern Med; 2015 Mar; 26(2):95-105. PubMed ID: 25676808
[TBL] [Abstract][Full Text] [Related]
37. [Safety and short-term efficacy of renal sympathetic denervation in the treatment of resistant hypertension].
Jiang XJ; Liang T; Dong H; Peng M; Ma WJ; Guan T; Zhang HM; Bian J; Xu B; Gao RL
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3265-8. PubMed ID: 23328511
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of renin-guided treatment of hypertension.
Smith SM; Campbell JD
Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
[TBL] [Abstract][Full Text] [Related]
39. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension.
Ukena C; Mahfoud F; Spies A; Kindermann I; Linz D; Cremers B; Laufs U; Neuberger HR; Böhm M
Int J Cardiol; 2013 Sep; 167(6):2846-51. PubMed ID: 22917547
[TBL] [Abstract][Full Text] [Related]
40. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
